Successful Treatment of Pigmented Purpuric Dermatoses With Abrocitinib: A Case Report

Pigmented Purpuric Dermatoses (PPD) are chronic conditions often resistant to standard treatments, creating a need for new therapies, particularly for those suffering from severe itching. This report details a patient with a year of refractory lower-extremity PPD who failed multiple oral and topical treatments. The patient was then successfully treated with oral abrocitinib (100 mg daily). Significant relief from pruritus occurred within 2 weeks, and substantial improvement in the skin lesions followed by the sixth week. After 3 months of treatment, lesions resolved to simple brown patches, with no recurrence seen during a four-month follow-up and no significant side effects noted. These results suggest that the JAK1 inhibitor abrocitinib possesses potential as a safe and highly effective treatment option for refractory PPD, warranting further clinical study.